Connect with Us
602 Park Point Drive, Suite 225, Golden, CO 80401 – +1 303.495.2073
© 2024 Medical Affairs Professional Society (MAPS). All Rights Reserved Worldwide.
In this white paper we will discuss various insights that should inform the creation and refinement of the iMC Strategy and Plan (iMC S/P), in addition to the traditional inputs that Medical Communications teams commonly use. The objectives are to (1) explain value of an insights-driven collaborative approach to creating an iMC S/P, (2) elucidate best practices for collecting and synthesizing integrated insights that are relevant to Medical Communications, and (3) operationalizing an insights-driven approach to create and update an iMC S/P.
The use and acceptance of real-world evidence (RWE) in the pharmaceutical and biotechnology industries has increased dramatically in the last 5 years. Approximately 70% of new drug and biologic regulatory submissions to the U.S Food and Drug Administration (FDA) now include RWE.1 Nearly 95% of pharmaceutical industry respondents, in a recent survey by Deloitte, expect RWE to play an important role in their companies by 2022.2 Medical Affairs (MA) professionals are in a unique position to champion the use of RWE internally and communicate its value both internally and externally. This white paper focuses on providing MA professionals with the background and history of RWE, and its potential applications in the biopharma industry, so that they may incorporate this knowledge into their areas of functional expertise, and ultimately, benefit patients and consumers in their healthcare decision-making.
A guide for Medical Communications cross-functional collaboration to develop an Integrated Medical Communications Strategy and Plan (iMC S/P) which is the roadmap for how a Medical Affairs team communicates its product vision and value proposition to internal and external stakeholders.
When quantitative and qualitative Field Medical KPIs and metrics are aligned with the organization’s strategic plan, these measurements demonstrate value. Defining and communicating this value is an essential task as Field Medical solidifies its role as a strategic pillar within the organization.
This paper discusses the sources and uses of non-registrational evidence and describes why Medical Affairs is positioned to lead and own the nRE Strategic Plan.
This white paper from the MAPS Medical Strategy & Launch Excellence Focus Area Working Group (FAWG) describes the elements of meaningful metrics in Medical Affairs and demonstrates how these metrics can be used to facilitate real actions and outcomes for Medical Affairs teams and the organization as a whole
This report shares the key insights from a MAPS special session on Field Medical engagement and provides further context from Medical Affairs colleagues who have first-hand knowledge of the ever-changing Field Medical role.
The importance of medical insights is well recognized across the pharmaceutical industry as a key driver for informing and shaping strategy and tactics. To gain a better understanding of this pivotal Medical Affairs activity, the Medical Affairs Professional Society (MAPS) conducted two membership surveys specifically addressing insights. The surveys highlighted a wide variation in how companies approach medical insights, without any obvious areas of best practice or common frameworks in use despite the current recognition of the importance and relevance of medical insights. The survey results indicate the need to identify a common framework across Medical Affairs for insight-related activities (i.e., insights or information generation, curation, collation, reporting, and utilization). Establishing such a framework is necessary to optimize medical insights’ impact and value in a broader organizational strategy.
This paper explores how moving from a fragmented approach focused on individual Medical Affairs channels (e.g., MSLs or Medical Information) to a more holistic, multi-channel, integrated approach to insights will create value for the organization, as well as for patients and the medical and scientific community.
Medical Affairs’ role in securing a bright future for pharma is undeniable, yet many before have struggled to bring forth concise and consistent descriptions that communicate the full range of benefits and expertise that Medical Affairs (MA) brings to the table. As a result, the wider understanding of MA’s role is not where it should be. To that end, this white paper explores the role and value of MA, backed up with commentary from industry leaders, as we define clear pillars of MA that communicate its true value. What’s more, we propose a short elevator pitch that MA professionals can use to quickly yet succinctly describe the importance of MA for every successful pharma venture in the future.
602 Park Point Drive, Suite 225, Golden, CO 80401 – +1 303.495.2073
© 2024 Medical Affairs Professional Society (MAPS). All Rights Reserved Worldwide.